Advertisement
Advertisement
NVAX
Novavax Inc
8.42
USDSponsored
+0.44
+5.48%
Apr 08, 16:00 UTC -4
Closed
Pre-Market
8.40
-0.02
-0.24%
NVAX Earnings Reports
Positive Surprise Ratio
NVAX beat 18 of 41 last estimates.
44%
Next Report
Date of Next Report
May 06, 2026
Estimate for Q1 26 (Revenue/ EPS)
$80.89M
/-$0.24
Implied change from Q4 25 (Revenue/ EPS)
-45.02%
/-318.18%
Implied change from Q1 25 (Revenue/ EPS)
-87.87%
/-108.19%
Novavax Inc earnings per share and revenue
On Jan 12, 2026, NVAX reported earnings of 0.11 USD per share (EPS) for Q4 25, beating the estimate of -0.49 USD, resulting in a 122.15% surprise. Revenue reached 147.14 million, compared to an expected 92.06 million, with a 59.82% difference. The market reacted with a +17.42% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 7 analysts forecast an EPS of -0.24 USD, with revenue projected to reach 80.89 million USD, implying an decrease of -318.18% EPS, and decrease of -45.02% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Pharvaris N.V. Ordinary Shares
Report Date
Apr 02, 2026 For Q4 25
Estimate
-$0.63
Actual
-$0.72
Surprise
-13.69%
Connect Biopharma Holdings Limited Ordinary Shares
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$1.44
Actual
-$1.91
Surprise
-32.66%
Innate Pharma S.A. ADS
Report Date
Apr 01, 2026 For Q1 26
Estimate
-$0.12
Actual
-$0.55
Surprise
-353.80%
OS Therapies Incorporated
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.13
Actual
-$0.50
Surprise
-260.49%
Imunon, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$1.19
Actual
-$1.99
Surprise
-66.18%
Kairos Pharma, Ltd.
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.07
Surprise
-28.68%
Soligenix, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.57
Actual
-$0.28
Surprise
+50.98%
BioAtla, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$12.24
Actual
-$8.00
Surprise
+34.64%
Sunshine Biopharma Inc.
Report Date
Apr 03, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.54
Surprise
-96.08%
CNS Pharmaceuticals, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$5.19
Actual
-$10.15
Surprise
-95.50%
FAQ
What were Novavax Inc's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Novavax Inc reported EPS of $0.11, beating estimates by 122.15%, and revenue of $147.14M, 59.82% above expectations.
How did the market react to Novavax Inc's Q4 2025 earnings?
The stock price moved up 17.42%, changed from $9.53 before the earnings release to $11.19 the day after.
When is Novavax Inc expected to report next?
The next earning report is scheduled for May 06, 2026.
What are the forecasts for Novavax Inc's next earnings report?
Based on 7
analysts, Novavax Inc is expected to report EPS of -$0.24 and revenue of $80.89M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement